Evaluating the Significance of Atypical and Malignant Breast Lesions Arising in Fibroadenoma of the Breast

Abstract

Context While fibroadenomas (FAs) are the most common benign neoplasm of the breast, little data exists about the clinical characteristics and prognostic value of FAs found to be directly associated with atypical and malignant lesions. Objective Cases of FA of the breast were reviewed to establish the exact clinical significance of these lesions involved by atypia and malignancy. Design All FA cases diagnosed on core needle biopsy (CNB) between 2013 and 2022 were screened to identify atypical and malignant lesions arising in FA. The relationship between CNB and excisional findings for each case was reviewed. Results A total of 1500 cases of FA diagnosed on CNB were identified. Among these, 23 cases showed atypical and/or malignant lesions within FA. The median age at diagnosis was 53 years. Of those 23 cases, five were LCIS, one was LCIS+ILC, one was LCIS+ALH, one DCIS+IDC, one was LCIS+DCIS, three were ADH, seven were ALH, and four were DCIS. For LCIS, the excision showed LCIS (2/5), LCIS + ALH (1/5), LCIS + DCIS (1/5), LCIS + DCIS + ALH (1/5). For DCIS, excisions showed Invasive carcinoma with mixed ductal and lobular features (1/4), LCIS + DCIS (1/4), LCIS + DCIS + IDC [classic and pleomorphic type] (1/4), no residual carcinoma (1/4). For ALH, excision showed ALH (2/7), no residual ALH (2/7), ALH+IDP (Intraductal Papilloma) (2/7), LCIS (1/7). For ADH, DCIS (1/3), and benign findings (2/3). For LCIS+ILC and DCIS+IDC, the excisional findings were the same. For LCIS+ ALH, the excisional findings showed benign findings with the radial scar (1/1). Conclusion There is a low percentage of FA harboring atypia or carcinoma. Due to the high upgrade rate following excision, complete excision of these lesions may guide recommended method of clinical management

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All human participants' procedures were approved by the Institutional Review Board of Lenox Hill Hospital, Northwell Health, New York, USA.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

留言 (0)

沒有登入
gif